1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Japan Oral Anti-Diabetic Drug Market - Introduction
4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence
5 Japan Oral Anti-Diabetic Drug Market Landscape
5.1 Historical and Current Market Trends (2018-2023)
5.2 Market Forecast (2024-2032)
6 Japan Oral Anti-Diabetic Drug Market - Breakup by Drugs
6.1 Biguanides
6.1.1 Overview
6.1.2 Historical and Current Market Trends (2018-2023)
6.1.3 Market Segmentation
6.1.3.1 Metformin
6.1.4 Market Forecast (2024-2032)
6.2 Alpha-Glucosidase Inhibitors
6.2.1 Overview
6.2.2 Historical and Current Market Trends (2018-2023)
6.2.3 Market Forecast (2024-2032)
6.3 Dopamine D2 Receptor Agonist
6.3.1 Overview
6.3.2 Historical and Current Market Trends (2018-2023)
6.3.3 Market Segmentation
6.3.3.1 Bromocriptin
6.3.4 Market Forecast (2024-2032)
6.4 SGLT-2 inhibitors
6.4.1 Overview
6.4.2 Historical and Current Market Trends (2018-2023)
6.4.3 Market Segmentation
6.4.3.1 Invokana (Canagliflozin)
6.4.3.2 Jardiance (Empagliflozin)
6.4.3.3 Farxiga/Forxiga (Dapagliflozin)
6.4.3.4 Suglat (Ipragliflozin)
6.4.4 Market Forecast (2024-2032)
6.5 DPP-4 inhibitors
6.5.1 Overview
6.5.2 Historical and Current Market Trends (2018-2023)
6.5.3 Market Segmentation
6.5.3.1 Onglyza (Saxagliptin)
6.5.3.2 Tradjenta (Linagliptin)
6.5.3.3 Vipidia/Nesina(Alogliptin)
6.5.3.4 Galvus (Vildagliptin)
6.5.4 Market Forecast (2024-2032)
6.6 Sulfonylureas
6.6.1 Overview
6.6.2 Historical and Current Market Trends (2018-2023)
6.6.3 Market Forecast (2024-2032)
6.7 Meglitinides
6.7.1 Overview
6.7.2 Historical and Current Market Trends (2018-2023)
6.7.3 Market Forecast (2024-2032)
7 Japan Oral Anti-Diabetic Drug Market – Breakup by Region
7.1 Kanto Region
7.1.1 Overview
7.1.2 Historical and Current Market Trends (2018-2023)
7.1.3 Market Breakup by Drugs
7.1.4 Key Players
7.1.5 Market Forecast (2024-2032)
7.2 Kansai/Kinki Region
7.2.1 Overview
7.2.2 Historical and Current Market Trends (2018-2023)
7.2.3 Market Breakup by Drugs
7.2.4 Key Players
7.2.5 Market Forecast (2024-2032)
7.3 Central/ Chubu Region
7.3.1 Overview
7.3.2 Historical and Current Market Trends (2018-2023)
7.3.3 Market Breakup by Drugs
7.3.4 Key Players
7.3.5 Market Forecast (2024-2032)
7.4 Kyushu-Okinawa Region
7.4.1 Overview
7.4.2 Historical and Current Market Trends (2018-2023)
7.4.3 Market Breakup by Drugs
7.4.4 Key Players
7.4.5 Market Forecast (2024-2032)
7.5 Tohoku Region
7.5.1 Overview
7.5.2 Historical and Current Market Trends (2018-2023)
7.5.3 Market Breakup by Drugs
7.5.4 Key Players
7.5.5 Market Forecast (2024-2032)
7.6 Chugoku Region
7.6.1 Overview
7.6.2 Historical and Current Market Trends (2018-2023)
7.6.3 Market Breakup by Drugs
7.6.4 Key Players
7.6.5 Market Forecast (2024-2032)
7.7 Hokkaido Region
7.7.1 Overview
7.7.2 Historical and Current Market Trends (2018-2023)
7.7.3 Market Breakup by Drugs
7.7.4 Key Players
7.7.5 Market Forecast (2024-2032)
7.8 Shikoku Region
7.8.1 Overview
7.8.2 Historical and Current Market Trends (2018-2023)
7.8.3 Market Breakup by Drugs
7.8.4 Key Players
7.8.5 Market Forecast (2024-2032)
8 Japan Oral Anti-Diabetic Drug Market – Competitive Landscape
8.1 Overview
8.2 Market Structure
8.3 Market Player Positioning
8.4 Top Winning Strategies
8.5 Competitive Dashboard
8.6 Company Evaluation Quadrant
9 Profiles of Key Players
9.1 Company A
9.1.1 Business Overview
9.1.2 Product Portfolio
9.1.3 Business Strategies
9.1.4 SWOT Analysis
9.1.5 Major News and Events
9.2 Company B
9.2.1 Business Overview
9.2.2 Product Portfolio
9.2.3 Business Strategies
9.2.4 SWOT Analysis
9.2.5 Major News and Events
9.3 Company C
9.3.1 Business Overview
9.3.2 Product Portfolio
9.3.3 Business Strategies
9.3.4 SWOT Analysis
9.3.5 Major News and Events
9.4 Company D
9.4.1 Business Overview
9.4.2 Product Portfolio
9.4.3 Business Strategies
9.4.4 SWOT Analysis
9.4.5 Major News and Events
9.5 Company E
9.5.1 Business Overview
9.5.2 Product Portfolio
9.5.3 Business Strategies
9.5.4 SWOT Analysis
9.5.5 Major News and Events
Company names have not been provided here as this is a sample TOC. Complete list to be provided in the final report.
10 Japan Oral Anti-Diabetic Drug Market - Industry Analysis
10.1 Drivers, Restraints, and Opportunities
10.1.1 Overview
10.1.2 Drivers
10.1.3 Restraints
10.1.4 Opportunities
10.2 Porters Five Forces Analysis
10.2.1 Overview
10.2.2 Bargaining Power of Buyers
10.2.3 Bargaining Power of Suppliers
10.2.4 Degree of Competition
10.2.5 Threat of New Entrants
10.2.6 Threat of Substitutes
10.3 Value Chain Analysis
11 Appendix